A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Pantoprazole
| Chemical Name | : | Pantoprazole |
|---|---|---|
| Catalog Number | : | CS-O-10995 |
| CAS Number | : | 102625-70-7 |
| Status | : | Available for Dispatch by 3-Apr-2023 |
| Category | : | Pantoprazole API Standards |
| Molecular Weight | : | 383.37 mol/g |
| Molecular Formula | : | C₁₆H₁₅F₂N₃O₄S |
| Therapeutic | : | Anti ulcer, Digestive system drugs |
Need custom pricing for Pantoprazole?
Please enter the following information to view price.
Shipping & Availability
| Status | : | Pantoprazole - Available for Dispatch by 3-Apr-2023 |
|---|---|---|
| Do you deliver in USA? | : | We offer free shipping of Pantoprazole in USA , Canada and major countries worldwide. |
| COA | : | View COA |
| MSDS | : | View Sample MSDS |
| Hazardous Compound | : | Yes |
More Information
| Chemical Name | : | Not availble |
|---|---|---|
| Payment mode | : | Credit / Debit / Purchase Order |
| Taxes | : | All prices are inclusive taxes |
| Refund Policy | : | 30 days money back guarantee |
| Canonical SMILES | : | COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC |
| Isomeric SMILES | : | COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC |
| InChI | : | InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21) |
| InchIKey | : | IQPSEEYGBUAQFF-UHFFFAOYSA-N |
| IUPAC Name | : | 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole |
| Exact Mass | : | 383.07513347 |
| Color | : | Off-white solid |
| Melting Point | : | 149-150 |
| Boiling Point | : | 586.9±60.0 °C at 760 mmHg |
| Solubility | : | Freely soluble in water. |
| Use Classification | : | Human drugs -> Pantoloc Control -> EMA Drug Category |
| Hazard Class | : | Acute Tox. 4 (100%) |
| Description | : | Pantoprazole is a member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. It has a role as an anti-ulcer drug, an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor, a xenobiotic and an environmental contaminant. It is a member of benzimidazoles, a member of pyridines, an aromatic ether, an organofluorine compound and a sulfoxide. It is a conjugate acid of a pantoprazole(1-). |
| Disposal Methods | : | SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations. |
| EC Number | : | 600-331-6 |
| Vapor Pressure | : | 1.25X10-12 mm Hg at 25 °C /Estimated/ |
| Toxicity Summary | : | **Rat Oral LD 50** 747 mg/kg **Tumorigenicity** Because of the chronic nature of GERD, there may be a potential for long-term administration of pantoprazole. In long-term rodent studies, pantoprazole was carcinogenic and its administration lead to rare types of gastrointestinal tumors. The relevance of these findings to tumor development in humans is unknown at this time. **Teratogenic Effects** This drug falls under pregnancy category B category. Reproduction studies have been performed in rats at oral doses up to 88 times the recommended human dose (RHD), as well as in rabbits at oral doses up to 16 times the RHD, and have shown no evidence of impaired fertility or harm to the fetus caused by pantoprazole. No adequate and well-controlled studies in pregnant women have been completed. Because animal reproduction studies are not always predictive of human response, this drug should only be used during pregnancy if clearly required. **Nursing Mothers** Pantoprazole and its metabolites have been found to be excreted in the milk of rats. Pantoprazole excretion in human milk has been found in a study performed with a single nursing mother after one 40 mg oral dose. The clinical relevance of this finding is not known, however, it is advisable to take note of this finding when considering pantoprazole use during nursing. Many drugs excreted in human breastmilk have a risk for serious adverse effects in nursing infants. |
| Antidoteand Emergency Treatment | : | Pantoprazole is not removed by hemodialysis. In cases of overdosage, treatment should be symptomatic and supportive |
| Human Toxicity Excerpts | : | /SIGNS AND SYMPTOMS/ Anaphylaxis has been reported with the use of IV pantoprazole sodium. Immediate medical intervention and drug discontinuance are required if anaphylaxis or other severe hypersensitivity reactions occurs. /Pantoprazole sodium/ |
